Insights / Blog Will the Supreme Court Review Whether FDA-Mandated Bioequivalence Testing to Maintain Approval Falls Within the § 271(e)(1) Safe Harbor? May 5, 2021
Insights / Blog Federal Circuit: A Biosimilar Applicant Must Provide Notice of Intent to Market a Biosimilar Product, No Exceptions May 5, 2021
Insights / Blog Biosimilars: Solicitor General Recommends Granting Certiorari in Amgen v. Sandoz May 5, 2021
Insights / Blog Digital Health Companies May Find a Faster Path to Market Under the FDA’s Digital Health Plan May 5, 2021
Insights / Media Coverage Can Companies Require the COVID-19 Vaccine? Fenwick’s Sheeva Ghassemi-Vanni Explains May 5, 2021
Insights / Blog Women Leaders in Digital Health See Rapid Growth and Increased Access Fueled by Pandemic May 5, 2021
